Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases
10.3760/cma.j.cn115355-20210205-00076
- VernacularTitle:非小细胞肺癌脑转移免疫检查点抑制剂治疗的研究进展
- Author:
Mei HUANG
1
;
Yanjing LI
;
Qingwei MENG
Author Information
1. 哈尔滨医科大学附属肿瘤医院呼吸内科，哈尔滨 150081
- Keywords:
Carcinoma, non-small-cell lung;
Neoplasm metastasis;
Brain neoplasms;
Immunosuppressive agents;
Molecular targeted therapy
- From:
Cancer Research and Clinic
2022;34(5):390-393
- CountryChina
- Language:Chinese
-
Abstract:
Brain metastasis is a common complication of non-small cell lung cancer (NSCLC) patients. About 25%-55% of patients with NSCLC will develop brain metastases, and the occurrence of brain metastasis predicts a poor prognosis. Traditionally, radiotherapy, chemotherapy, targeted therapy and surgery are the main treatment options for NSCLC patients with brain metastases. In recent years, with the emergence of immune checkpoint inhibitors (ICI), the survival of NSCLC patients with brain metastases has been significantly improved. This article reviews the research progress of ICI treatment for NSCLC patients with brain metastases in order to provide new treatment strategies.
